These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8809659)

  • 1. Treatment of metastatic breast cancer by navelbine, mitoxantrone and continuous infusion 5-fluorouracil (FMN regimen): results of a pilot study.
    Azim HA
    J Infus Chemother; 1996; 6(2):102-6. PubMed ID: 8809659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
    Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
    Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
    In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.
    Berruti A; Bitossi R; Bottini A; Bonardi S; Donadio M; Nigro C; Bertetto O; Danese S; Bertone E; Sarobba MG; Farris A; Katsaros D; Castiglione F; Volpe T; Lattuada S; Mancarella S; Dogliotti L
    Eur J Cancer; 2005 Jan; 41(2):249-55. PubMed ID: 15661550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
    Klaassen U; Wilke H; Müller C; Borquez D; Harstrick A; Seeber S
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
    Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A
    Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial.
    Deprés-Brummer P; Berthault-Cvitkovic F; Lĕvi F; Brienza S; Vannetzel JM; Jasmin C; Misset JL
    J Infus Chemother; 1995; 5(3 Suppl 1):144-7. PubMed ID: 8528975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
    Ikeda M; Okusaka T; Ueno H; Takezako Y; Morizane C
    Cancer; 2005 Feb; 103(4):756-62. PubMed ID: 15637692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.
    Gebbia V; Borsellino N; Testa A; Tirrito M; Varvara F; Cucchiara A; Mauceri G; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(4C):3553-7. PubMed ID: 10629652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer.
    Pavesi L; Preti P; Da Prada G; Pedrazzoli P; Poggi G; Robustelli della Cuna G
    Anticancer Res; 1995; 15(2):495-501. PubMed ID: 7763029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion.
    Gebbia V; Mauceri G; Testa A; Tirrito M; Varvara F; Cucchiara A; Borsellino N; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(3B):2289-92. PubMed ID: 10472346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
    Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
    Chu L; Sutton LM; Peterson BL; Havlin KA; Winer EP
    J Infus Chemother; 1996; 6(4):211-6. PubMed ID: 9229318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
    Delozier T; Guastalla JP; Yovine A; Levy C; Chollet P; Mousseau M; Delva R; Coeffic D; Vannetzel JM; Zazzi ES; Brienza S; Cvitkovic E
    Anticancer Drugs; 2006 Oct; 17(9):1067-73. PubMed ID: 17001180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.